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Methods: Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug
development techniques, we investigate the properties of NGP 555, a clinical-stage g-secretase
modulator.
Results: NGP 555 shifts amyloid peptide production to the smaller, nonaggregating forms of amyloid.
Our preclinical studies show beneficial effects on amyloid biomarkers, pathology, and cognition. NGP
555 has successfully completed chemistry, pharmacology, toxicity, metabolism, and safety studies.
Discussion: Abundant data support Ab42 as a target for prophylactic or early-stage intervention ther-
apies in AD. The g-secretase modulator, NGP 555 is being actively developed in human clinical trials
for the prevention of Alzheimer’s disease with the overall aim to achieve an appropriate balance of
potency/efficacy on reducing the toxic forms of amyloid versus safety.
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Alzheimer’s disease (AD) is a progressive and fatal brain
disease, currently afflicting as many as 5.4 million Americans
and one in eight people over age 65 years. ADwill become an
even greater public health issue with the aging of the baby
boompopulation. It is estimated that by 2050, 11 to 16million
Americans will suffer from AD dementia [1,2]. Therapeutic
interventions that can effectively treat or prevent AD
are urgently needed. AD is a neurodegenerative disease. are employees and shareholders of NeuroGenetic
thor.
kounnas@neuro-genx.com
16/j.trci.2016.09.003
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cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).characterized by two distinct pathologies: (1) neurofibrillary
tangles, comprised mostly of hyperphosphorylated tau, and
(2) amyloid plaques, consisting primarily of amyloid
b-peptides (Ab) [3–5]. Recent work in autosomal
dominantly inherited AD patients indicates that pathologic
alterations in the brain and cerebrospinal fluid are evident
approximately 10–20 years before dementia can be detected
[6,7]. Notably, several biomarker changes occur in the years
before dementia including early reduction in Ab42 and later
increase in tau concentrations in the cerebrospinal fluid
(CSF), hippocampal and regional brain atrophy, and brain
amyloid plaque deposits [8–10].
Ab42 is derived from a larger protein, the amyloid precur-
sor protein (APP) [11], by sequential cleavage steps requiring
two enzymes. However, as the aging process occurs or underon behalf of the Alzheimer’s Association. This is an open access article under
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the accumulation of the toxic form of amyloid, Ab42, is
increased. Numerous genetic, biological, and clinical investi-
gations suggest that accumulation of Ab42 is likely one of the
earliest factors in the pathogenesis of AD [12–17].
In an effort to prevent the damaging effects of Ab42,
several lines of drug discovery have focused on inhibiting
the formation of Ab42. Many efforts have been based on
the development of g-secretase inhibitors (GSIs), BACE in-
hibitors, or the development of anti-Ab antibodies. Other
approaches include NSAID-like g-secretase modulators
(GSMs) and non-NSAID-like GSMs [18–22].
A number of amyloid therapies to date have failed in clin-
ical studies. The reasons for these failures are that either
these agents were tested in patients with disease that was
too far advanced or that these agents showed mechanism-
based toxicities; for example, GSIs, whose failure was
partially attributed to Notch inhibition and APP-carboxy-
terminal fragment accumulation [23–25]. Multiple BACE-
1 inhibitors and anti-Ab antibody trials are now underway
in early patient populations, and those results may help to
confirm the amyloid hypothesis.
GSMs identified to date can be categorized into three
groups and have been reviewed extensively [22,26–30]: (1)
NSAID-derived GSMs with flurizan and follow-up mole-
cules generally showing lack of potency in the clinic. It is
notable that this class of modulators acts with a different
mechanism of action (MOA) as compared to NGP 555
[22,30,31], (2) Naturally derived molecules with an
unknown target such as Satori’s GSM (SPI-1865) which
showed preclinical renal toxicity (reported via press
release, 2012), and (3) Heterocyclic GSMs such as E2012,
E2212, and BMS 932,481—molecules which have a
similar MOA to NGP 555 and show CNS or peripheral
biomarker efficacy in the clinic. However, these molecules
failed due to lack of an adequate safety margin/compound
structure-based toxicities [21,22,32,33].
NGP 555 has been cited as a first of type GSM (28, 34, US
Patent # 7,244,739, 2004) and has a heterocyclic structure
but does have several important distinctions that are
described below in the results section that are thought to
be the necessary improvements to render a safe and effective
drug product. To date, no GSM has been adequately tested in
the clinic to determine whether the GSM mechanism will
translate preclinical findings on Ab biomarker reductions
(Ab42 CSF levels and brain amyloid plaques) to prevention
of cognitive decline with an adequate safety margin.
Herein, we describe our clinical stage small-molecule
modulator of Ab42 production, NGP 555.2. Methods
2.1. In vitro cell-based assays
SH-SY5Y-APP cells, Tg2576 mixed brain cultures, or
C57 mixed brain cultures were treated with various concen-trations of NGP 555 or NGP 328, in triplicate wells, for
18 hours. Media was collected and analyzed for Ab peptides
using Meso Scale triplex ELISA (Ab38 and Ab42) as
previously detailed in [34].
2.2. Ab Meso Scale assay
The Ab peptides were quantified using the triplex Meso
Scale kit (catalog #K11141A-3 for the human Ab sequence
or K11141E-2 for the rat Ab sequence) and Meso Scale
Sector Imager 6000 for detection after the manufacturer’s
recommended protocol.
2.3. In vivo studies
All animal care protocolswere followed in accordancewith
the Institutional Animal Care and Use Committee of the uni-
versity or company at which the studies were conducted.
2.4. Brain and plasma Tg2576 studies
Tg2576 mice (w3 months) were dosed at indicated dose
levels with NGP 328 in 80% PEG/water once-daily for
3 days. Six hours following dosing on the last day, blood
was collected from all mice via cardiac puncture under iso-
fluorane anesthesia into heparinized tubes and centrifuged
(10,000! g for 10 minutes) to isolate plasma. Brain hemi-
spheres used for biochemical analyses were extracted in
70% formic acid, neutralized with 2M Tris base, and the
amount of Ab was measured as previously detailed in [34].
2.5. CSF studies
Normal Sprague–Dawley male rats (250–300 g) were
administered NGP 555 in 80% PEG orally or vehicle only,
n 5 10/group. Rats were dosed once-daily for a single-
dose or 14 days of dosing. After the final dose, CSF samples
were either collected at varying time points or a single time
point post-last dose as indicated in Figure legends. Rats were
deeply anesthetized with isoflurane, and CSF was collected
from the cisterna magna. Samples were tested for Ab levels
using the Meso scale ELISA (K11141E-2 for the rat Ab
sequence).
2.6. Y-maze
Transgenic mice (Tg2576 line expressing the APP-Swe
mutation) [25] and non-transgenic age-matched littermates
(n 5 a minimum of 12/group) were treated with vehicle,
NGP 555 (25 mg/kg) or semagacestat (a g-secretase inhibi-
tor at 25 mg/kg) once-daily for 30 consecutive days (starting
at 5 months of age). Mice were allowed to lick vehicle or
drugs orally in a cherry syrup mixture to avoid adverse ef-
fects from chronic oral gavaging, and experimenters
confirmed that mice (housed alone) finished each dose. At
6 months, mice were assessed on the Y-maze behavior test.
This test included a determination of spontaneous alterna-
tion behavior, a measure of spatial working memory,
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behavior test was chosen based on the deficits seen at this
age range in the Tg2576 model, and the statistical power
to reproduce these deficits with n 5 12 per group as deter-
mined by previous studies (unpublished findings from Dr.
Amanda Roberts at the Mouse Behavioral Assessment
Core at Scripps Research Institute (La Jolla, CA). Each
mouse received one 5-minute trial during which arm
choices, and total numbers of arm entries were recorded.
Spontaneous alternation, expressed as percentage, refers to
the ratio of arm choices differing from the previous two
choices, to the total number of arm entries.2.7. Morris water maze
Transgenic Tg2576 mice were obtained from Taconic
[35] and crossed with Reln fl/fl mice [36]. The Reln fl/fl;
Tg2576 line was then crossed with B6.Cg-Tg(CAG-cre/
Esr1)5Amc/J mice, referred to as CAG-Cre mice (obtained
from Jackson Laboratories [37]). Animals were group-
housed in a standard 12-h light cycle and fed ad libitum stan-
dard mouse chow. At two months, the resulting Reln fl/fl;
Tg2576 mice with or without CAG-Cre (Cre1 and Cre2)
were given daily intra-peritoneal injections with 135-mg/
kg tamoxifen (Sigma) dissolved in sunflower oil for
5 days. The resulting reelin conditional knockout (cKO)
and controlmicewere then aged for approximately 7months.
At that time, they were treated orally with NGP 555 in cherryFig. 1. NGP 328 reduce Ab42 and Ab40 increase Ab38 in SH-SY5Y-APP cells an
concentrations of NGP 555 or NGP 328, in triplicate wells, for 18 hours. Media w
(Ab38, Ab40, and Ab42) and total Ab ELISA as described in Kounnas, et al. 2010. IC
Tg2576 studies, mice were dosed once-daily for 3 days. Six hours after the last dos
and plasma was collected, and Ab levels were quantified using a Meso Scale triple
Raw signals were converted to pg/well based on standard peptide curves, Data ar
vehicle control. Chemical structures for the compounds are shown for NGP 32
NGP 328 structure; (C) NGP 328 in vitro SH-SY5Y data; (D) NGP 328 Tg2576 p
viously reported as compound 4 [35].syrup or cherry syrup vehicle as described above for 28 days
before the start of the Morris Water Maze (MWM) and
continued until the completion of behavioral testing. This
behavior test was chosen based on the optimal deficits
seen in this model.2.8. Notch in vivo assays
Male and female Crl:CD(SD) rats, approximately 7–
8 weeks, were administered vehicle or NGP 555 (150 mg/
kg) via oral gavage daily for 14 consecutive days. The number
of goblet cells in the jejunum and in the ileum was counted
using Alcian blue/PAS stained sections from all animals in
the control and 150 mg/kg/day groups. Digital images were
captured from scanned slides of the jejunum and ileum using
the Hamamatsu slide scanner and NDP software. Image-Pro
Plus software was used to measure the length of 10 well-
oriented, intact crypt-villus units for each tissue (jejunum
and ileum) of each animal [38], and the goblet cells along
the left side of the crypt-villus axis were enumerated [39].3. Results
High throughput screening for lowering Ab42 levels in
cells without changes on Notch processing, followed by
extensive medicinal chemistry efforts, yielded several
lead candidates, including NGP 555 and NGP 328 [40].
Data in Fig. 1 show the chemical structures of two leadd Tg2576 plasma and brain. SH-SY5Y-APP cells were treated with various
as collected and analyzed for Ab peptides using Meso Scale triplex ELISA
50 or EC50 values determined from nonlinear fitted curves are indicated. For
e, brain (then extracted with formic acid and neutralized with 2-M Tris base)
x kit which simultaneously measured Ab38, Ab40, and Ab42 in a single well.
e shown as percent vehicle control. *P , .05 by one-tailed ANOVA versus
8 and NGP 555 with ring designations indicated. (A) NGP structure; (B)
lasma data; (E) NGP 328 Tg2576 brain data. NGP 555 data have been pre-
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in vitro potency profiles for modulating Ab peptides for
NGP 328; the in vivo lowering of Ab42 and raising of
Ab38 in the plasma (panel D) and brain (panel E) after
dosing once daily for 3 days in Tg2576 mice. Similar
data for NGP 555 were previously published [34]. Both
compounds potently lower Ab42 in cell cultures (9 nM)
while increasing shorter forms of Ab and have similar
in vivo efficacy profiles and potency. However, subsequent
rat toxicity studies revealed liver toxicity as a liability of
NGP 328 at efficacious doses (10 mg/kg and above).
NGP 555 in contrast had markedly higher exposure levels
versus efficacious levels (w20-fold higher) before liver en-
zymes were increased in the rat studies. In addition for NGP
555, beagle dog toxicity studies revealed no increase in
liver enzymes up to and beyond the no-observable adverse
effect level (NOAEL). These data led us to the hypothesis
that the single differential chemical feature, the inclusion
of a methoxy-group on ring B (Panel B) in comparision
to the fluoro-group on NGP 555 (Panel A) was a contrib-
uting factor in hepatic toxicity. For this reason, NGP 555
was chosen as a clinical candidate.
The scope of chemical structures synthesized and tested
for brain bioavailability and Ab42 levels has been presented
[40]. The polar arylimidazole end of NGP 555 has been
optimal for most series of GSMs reported [28], but most
GSM candidates include a methoxy group in the B-ring for
increased water solubility. We chose the fluoro group inFig. 2. Model of the human g-secretase complex and computational docking of NG
Vina. (A) Ribbon representation of g-secretase. NGP 555 docks between TM dom
castrin (NCT). The PAL sequence motif, implicated in substrate recognition, reside
(B) Surface representation of g-secretase. The polar A ring of NGP 555 docks at th
lipophilic D ring in the greasy pocket environment of F175, F176, and F179 of Pthe B-ring, which makes the imidazole less basic but retains
potency and avoids binding at ancillary sites. The methoxy
group confers water solubility, but less brain distribution
and faster metabolism in the liver, as seen for NGP 328
compared to NGP 555. In support of our findings, liver
toxicity is given as the reason for discontinuing several me-
thoxy containing GSMs [28,33]. A recent review of GSMs
[29] noted that NGP 555 has significant potency but suffers
from poor calculated “drug-like” properties. In contrast to
these calculated properties, NGP 555 has very good brain
penetration/absorption, distribution, metabolism, and excre-
tion (ADME) properties; these features are based on in vivo
results rather than in vitro or calculated properties and are the
basis for NGP 555 being a preferred clinical candidate.
Another potential advantage of NGP 555 is its optimal shape
for docking at the PEN-2/PS1 site of gamma secretase [41].
This hypothetical docking site was anticipated by binding
studies [34,42] and supported by energy plots and docking
studies revealed in Fig. 2. Low-energy rotation models
show NGP 555 prefers to have four coplanar rings with
A-B-C linear and C-D about 120 (hockey stick shape).
The polar A ring docks at PS1/PEN-2, the B and C rings
at the PS1/Nicastrin interface, and the lipophilic D ring in
the hydrocarbon pocket (F175, F176, and F179) of PS1.
Fig. 2 shows a model based on an atomic structure of hu-
man g-secretase [43] and the result of computational dock-
ing of NGP 555 using AutoDock Vina, that is, the 1st
ranked docking site (as the energy minimum) from repeatedP 555. Docking of NGP 555 to g-secretase was carried out using AutoDock
ains 3 and 4 of PS1-NTF and near non-TM alpha helices of PEN-2 and Ni-
s in TM9, and catalytic residues D247 and D385, in TM6 and TM7, of PS1.
e PS1/PEN-2 interface, the B and C rings at the PS-1/NCT interface, and the
S1.
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pected to dock between PEN-2 and transmembrane (TM)
domains 3 and 4 of PS1-NTF. Activation of the PS1 catalytic
site (Fig. 2A; D247 and D385 catalytic residues residing in
TM6 and TM7, respectively) depends on the binding of
PEN-2 to TM4 of PS1-NTF, which has an allosteric effect
on TM6 of PS1 [41]. In the model, the transmembrane helix
of the putative substrate is in close proximity to Nicastrin
where NGP 555 docks (Fig. 2B). The alkyl pattern of the
D-ring is optimal for this docking [40]. Thus, NGP 555
maymodulate g-secretase by (a) affecting the interaction be-
tween PEN-2 and TM4 of PS1-NTF, thereby modulating cat-
alytic activity through an allosteric effect on TM6 of PS1,Fig. 3. NGP 555 effectively lowers Ab42 in CSF. (A) NGP 555 lowers Ab42 in CSF
dose orally with NGP 555 in 80% PEG (15 mg/kg) or vehicle only, n5 10/group.
using specific ELISAs to measure Ab alloforms. *P, .05 by unpaired t test versus
male rats (250–300 g) were dosed once-daily for 14 days orally with NGP 555 in 80
All samples were quantified using specific ELISAs to measure Ab alloforms. *P, .
Normal Sprague–Dawleymale rats (250–300 g) were dosed once-daily for 14 days
later, CSF was collected. All samples were quantified using specific ELISAs to m
NGP 555 lowers Ab42 and raises Ab38 in CSF. Normal Sprague–Dawley male rats
PEG (37.5mg/kg), n5 10/group. Eight hours later, CSFwas collected. All samples
unpaired t test versus vehicle control.and/or (b) affecting cleavage through changes in substrate
conformation near Nicastrin or the substrate cavity [34,44].
Previous data demonstrated that NGP 555 efficiently
crosses the blood-brain barrier, has a brain:plasma ratio of
0.93 (in Tg2576 mice) and shows in vivo efficacy for
lowering the biomarker Ab42 in rodent studies for brain
and plasma. Notably, NGP 555 (aka Compound 4) potently
and selectively reduced Ab42 in neurons derived from hu-
man pluripotent stem cells from patients carrying presenilin
1 mutations [45,46].
Chronic administration of NGP 555 (milled into chow) to
Tg2576 mice resulted in a significant reduction of amyloid
plaques [34].. Normal Sprague–Dawley male rats (250–300 g) were administered a single
CSF was collected at the indicated time points. All samples were quantified
vehicle control. (B) NGP 555 lowers Ab42 in CSF. Normal Sprague–Dawley
% PEG (0–37.5 mg/kg), n5 10/group. Eight hours later, CSF was collected.
05 by unpaired t test versus vehicle control. (C) NGP 555 raises Ab38 in CSF.
orally with NGP 555 in 80%PEG (0–37.5mg/kg), n5 10/group. Eight hours
easure Ab alloforms. *P , .05 by unpaired t test versus vehicle control. (D)
(250–300 g) were dosed once-daily for 14 days orally with NGP 555 in 80%
were quantified using specific ELISAs tomeasure Ab alloforms. *P,.05 by
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concentrations of Ab alloforms in CSF from male
Sprague–Dawley rats, relative to vehicle-treated control
rats. Both a time course at 15 mg/kg (single dose) and
dose-response (1.75–37.5 mg/kg) given once-daily for
14 days were conducted.
Fig. 3 reveals NGP 555 significantly lowered Ab42 in the
CSF at time points from 8–10 hours post dose, panel B shows
that reduction of Ab42 levels was significant at 3.75 mg/kg
and above, and panel C shows an increase in Ab38 levels
at 15 mg/kg and above. When combining the reduction of
Ab42 with an increase in Ab38, NGP 555 was effective at
raising CSFAb38/42 ratio at 1.87 mg/kg and above (panel D).
To examine whether chronic administration of NGP 555
(1 month of treatment) could prevent the cognitive deficits
observed in Tg2576 mice at 6 months, mice non-Tg and
Tg were treated orally once daily (25 mg/kg) for 1 month
(from age 5 months to 6 months) then tested in the Y-maze
cognition test.
Data for this study are shown in Fig. 4, Panel A. The re-
sults show that the Tg vehicle-treated mice showed a 25%
decline in performance as compared to non-Tg vehicle-
treated mice (P , .001). NGP 555-treated Tg mice showed
a significant protection from decline with.65% less decline
(P, .005) when comparing the differential of Tg to non-Tg
vehicle-treated mice. A control g-secretase inhibitor, sema-
gacestat, did not demonstrate significant protection from
decline as compared to the non-Tg treated vehicle. Fig. 4,
Panel B confirms target engagement in the brain and plasma
for both compounds. NGP 555 showed the expected profile,Fig. 4. NGP 555 showed beneficial effects in the Y-maze behavioral test in a Tg257
(cherry syrup), NGP 555 (25 mg/kg), or semagacestat, gamma-secretase inhibitors
were dosed with each treatment arm. (A) Mice were assessed in the Y-maze (work
Data were collected on the total arm choices and arm choice as compared to the prev
which is a measure of the ratio of arm choices differing from the previous two cho
performed using a 2-way ANOVAwith genotype and drug as the factors (Graphpa
Three hours after final dose, brain (then extracted with formic acid and neutralized w
using a Meso Scale triplex kit which simultaneously measured Ab38, Ab40, and Ab
peptide curves, and the data then collated as pg/mL for each group. Data are showrevealing statistically significant reductions of Ab42 and
Ab40 in both brain and plasma while increasing Ab38 in
plasma. Ab38 in the brain was modestly increased. Semaga-
cestat showed significant reductions of all Ab alloforms in
both brain and plasma.
Because mice are remarkably resilient to Ab accumula-
tion, display little neuronal cell death and show cognitive
impairment due to synaptic suppression only after exorbi-
tantly high amyloid accumulation, NGP-555 was tested in a
second mouse model, the reelin cKO mouse model, using
another behavioral endpoint (Morris Water Maze). Reelin is
highly expressed in the brain and is a ligand for ApoER2
and VLDLr, both members of the low-density lipoprotein re-
ceptor family. Mice-lacking reelin are exquisitely sensitive to
the effect of Ab both at a synaptic and behavioral level [36];
thus, we hypothesized that treatment with NGP-555 might
rescue the learning deficit caused by the moderate amount
of synapse suppressing Ab42 accumulation that would occur
in ,1-year-old Tg2576 mice. 6–10-month-old Tg2576;
reelin cKO and Tg2576 control mice were treated with
NGP-555 or vehicle control daily for 28 days then trained
on the Morris Water Maze. There was no significant differ-
ence in acquisition of the task (Fig. 5A), although a trend to-
wards a deficit was observed in the vehicle-treated Tg2576;
reelin cKO mice. As previously shown, the Tg2576; reelin
cKO mice treated with vehicle were markedly impaired on
the probe trial compared to control mice. This deficit was
rescued by treatment with NGP 555 (Fig. 5B) (P , .05).
The safety, absorption, distribution, metabolism and
excretion (ADME) properties of NGP 555 have been studied6mousemodel.Micewere treated orally once-daily for 1month with vehicle
(25 mg/kg). Tg2576 transgenic (Tg) or non-transgenic littermates (non-Tg)
ing memory test) with the experimenter blinded to genotype and treatment.
ious choice. Data expressed as % spontaneous alteration (Mean1/2 SEM),
ices to the total number of arm entries, was plotted. Statistical analysis was
d, San Diego, CA). **P, .05 by 2-way ANOVA versus vehicle control. (B)
ith 2-M Tris base) and plasmawere collected, and Ab levels were quantified
42 in a single well. Raw signals were converted to pg/well based on standard
n as pg/mL. **P , .05 by one-tailed ANOVA versus vehicle control.
Fig. 5. NGP 555 showed beneficial effects in the Morris Water Maze in the Tg2576; reelin conditional knockout model. Mice were treated orally once-daily for
28 days with vehicle (cherry syrup) or NGP 555 (25mg/kg). Theywere treated again at the end of behavioral testing each day through theMWM. (n5 8 vehicle-
treated Tg2576; n5 9 NGP 555-treated Tg2576; n5 13 vehicle-treated Tg2576; reelin cKO; n5 15NGP 555-treated Tg2576; reelin cKO). Data represented as
mean6 S.E.M. (A) Tg2576; reelin cKO and Tg2576 mice were trained on 4 trials per day over 10 days to find a hidden platform using cues on the wall. 2-way
ANOVA revealed a significant effect of time (P, .001) but not of genotype (P. .05) on learning. (B) On day 11, the platformwas removed and time spent in the
target quadrant over 60 seconds was recorded. 2-way ANOVA revealed a significant effect of time (P , .001) and a significant interaction between time and
genotype (P, .05) on learning. Post-hoc analysis revealed a significant difference between vehicle and NGP 555-treated Tg2576; reelin cKOmice in the target
quadrant (*P , .05).
Table 1
NGP 555 does not affect the goblet cells in the ileum or jejunum in 150 mg/
kg treated rats (14 days dosing). Goblet cells in the ileum or jejunum were
counted using Alcian blue/PAS
Dosage (mg/kg/day)
Males Females
0 150 0 150
Mean ratio of Goblet cell number to Crypt-Villus axis length, ileum
Mean Ratio 0.071 0.066 0.067 0.068
STD 0.006 0.007 0.007 0.008
Mean ratio of Goblet cell number to Crypt-Villus axis length, jejunum
Mean Ratio 0.066 0.064 0.068 0.072
STD 0.004 0.006 0.012 0.007
Abbreviation: STD, Standard deviation.
NOTE. Digital images were captured from scanned slides of the ileum
using the Hamamatsu slide scanner and NDP software. Image-Pro plus soft-
ware was used to measure the length of 10 well-oriented, intact crypt-villus
units for each tissue of each animal and data were analyzed by Student t test.
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brain-penetrant with a brain:plasma ratio ofw0.93 in mice.
NGP 555 was assessed to be negative for cross-reactivity in a
Cerep screen against receptors and enzymes and for its po-
tential to inhibit hERG channels. Cardiopulmonary studies
in conscious, ambulatory Beagle dogs showed no adverse ef-
fects up to 125 mg/kg on cardiovascular and pulmonary end-
points. GLP in vitro genotoxicity studies (bacterial
mutagenicity and cytogenetic examination of chromosomal
damage) as well as GLP in vivo testing of the clastogenic po-
tential of NGP 555 in rat bone marrow showed negative re-
sults for the genotoxic potential of NGP 555. Effects on
metabolism were studied, NGP 555 was largely devoid of
CYP450 inhibition and induction, and the major metabolite
was identified as a carboxylic acid analog of NGP 555.
Repeat-dose toxicology studies in rat (14 days) at 37.5, 75,
and 150 mg/kg have established the dose-limiting effects are
on liver parameters including liver enzymes, weights, and
histology. Routine eye examinations did not reveal toxicity
however longer term toxicology studies will be needed to
adequately address the potential for optic concerns based
on the toxicity observed by another structurally distinct
GSM [32]. After 14 days of dosing in male rats, the AUC
measured at the NOAEL (37.5 mg/kg) was 25,779 ng$h/
mL. compared to the AUCmeasured at 3.75 mg/kg (the mini-
mally effective dose for lowering CSF Ab42) of 1092 ng$h/
mL. These data indicate a large therapeutic window (.20-
fold) between ability to lower CSF Ab42 with 14 days of
dosing versus the NOAEL in rats. Additionally, the potential
for known Notch-related effects on the gastrointestinal (GI)
tract were evaluated in tissues from rats treated for 14 days
with NGP 555 at 150 mg/kg resulting in exposure levelsexceeding 100,000 ng$h/mL. Table 1 shows the result of
the histologic examination of GI tissue with no differences
in goblet cell number and density between groups. This is a
significant finding since Notch-related toxicity which mani-
fests as goblet cell metaplasia is a key liability for first gener-
ation g-secretase inhibitors [24].
A solid dosage formulation was developed to accomplish
beagle dog toxicity studies. Repeat-dose Beagle dog toxicity
studies (28 days) revealed lower food consumption and
weight loss with reversible adrenal gland necrosis but
without effects on the liver at 50 mg/kg and above.
In summary, NGP 555, a small molecule disease-
modifying amyloid therapy, has emerged as a compelling
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profile, preclinical efficacy, safety, and ADME properties.4. Discussion
NGP 555, a molecule aimed at preventative therapy for
AD, has been successful in achieving good oral absorption,
brain penetration, CNS activity, and specificity for a lipid-
based membrane target preclinically [34].
NGP 555 acts by binding directly to the g-secretase
enzyme complex via Pen-2/PS1-NTFs without inhibiting
ε-site proteolysis of amyloid precursor protein (APP),
Notch, or E-cadherin. NGP 555 potently inhibits the produc-
tion of Ab42 and Ab40 and causes a concomitant increase in
the levels of Ab38 and Ab37. NGP 555 crosses the blood-
brain barrier and has a brain:plasma ratio of 0.93 (in
Tg2576 mice) [34] which demonstrates in vivo efficacy
for lowering the biomarker Ab42 in rodent studies for brain,
cerebrospinal fluid (CSF), and plasma while raising Ab38.
Chronic administration (NGP 555 milled into chow) to
Tg2576 mice resulted in a significant reduction of amyloid
plaques [34]. Studies addressing the effects of chronic
administration of NGP 555 on cognition in a transgenic
mouse model demonstrated that NGP 555 was able to
significantly prevent cognitive deficits in Y-maze perfor-
mance (a measure of working and spatial memory) and in
the Morris water maze (a measure of spatial learning and
memory). Our data demonstrate that a relatively modest
decrease in CSF Ab42 (20%–40%) plus the increase in the
shorter forms after acute or subchronic dosing in rodents
translates into a robust reduction in AD-pathology [34].
NGP 555 has demonstrated protection from cognitive
decline in two independent mouse studies using different
memory and learning tasks.
The quest to find a GSM with the ideal balance of safety,
potency, and efficacy in humans is ongoing. Some groups
focus efforts on calculated drug-like properties or water sol-
ubility [47–49], whereas others have demonstrated a
translation of empirical ADME properties across
preclinical species to humans [50]. We are taking an empir-
ical data-driven approach, using efficacy, Ab biomarkers,
ADME properties, and toxicology/safety profiles preclini-
cally to drive our choice of clinical candidates. The transla-
tion of these results and success in the clinic will ultimately
determine the best path forward for the GSM field.Acknowledgments
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1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and pre-
sented data. There are numerous descriptions of
amyloid approaches and g-secretase modulators,
and they are clearly cited. The innovation with NGP
555 is the improvement in the molecule’s properties
including structure, efficacy, and safety margins.
2. Interpretation: In characterizing NGP 555, a modu-
lator of amyloid production, we describe our hypoth-
esis that NGP 555 is a preferred molecule because of
its chemical structure, proposed 3-D shape, and its
ability to effectively (and selectively) target amyloid
biomarkers and pathology while preventing cogni-
tive decline preclinically.
3. Future directions: The article provides key informa-
tion on the preclinical findings and efficacy profile
of NGP 555 and provides the rationale to conduct
future clinical studies to test the amyloid hypothesis
in humans with a g-secretase modulator.References
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